“…1, 2, 4, 5 However, some patients with high cardiovascular risk either do not achieve adequate LDL‐C reductions on statins, or are intolerant to statins and therefore receive suboptimal statin doses or discontinue statin therapy, and thus remain at increased risk of cardiovascular events. For such patients, additional and/or alternative nonstatin lipid‐lowering treatment options should be considered 4, 6, 7, 8, 9, 10, 11, 12…”